Insight Molecular Diagnostics Inc 8-K, filed Feb 22, 2021

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

Pursuantto Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 18, 2021

OncoCyteCorporation

(Exact name of registrant as specified in its charter)

15Cushing

Irvine,California 92618

(Address of principal executive offices)

(949)409-7600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Forward-LookingStatements

Anystatements that are not historical fact (including, but not limited to statements that contain words such as “may,”“will,” “believes,” “plans,” “intends,” “anticipates,” “expects,”“estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actualresults to differ materially from the results anticipated in these forward-looking statements are contained in OncoCyte Corporation’sAnnual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (“SEC”)under the heading “Risk Factors” and in other filings that Oncocyte may make with the SEC. Undue reliance should notbe placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlyingthese statements may change. Except as required by law, Oncocyte disclaims any intent or obligation to update these forward-lookingstatements.

Referencesto “Oncocyte,” “we,” “us,” and “our” are references to OncoCyte Corporation.

Theinformation contained in Item 7.01 of this Report and the webcast referenced therein shall be deemed “furnished” andnot “filed” under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by OncoCyteunder the Securities Act of 1933, as amended, or the Exchange Act except as may be expressly set forth by specific reference insuch filing.

Item7.01 - Regulation FD Disclosure

On Thursday, February 18, 2021, Oncocyte participated in a virtual Fireside Chat with Diagnostics Analyst Mark Massaro at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The Fireside Chat can be accessed as a webcast on Oncocyte’s website at www.oncocyte.com or at the following internet website address: wsw.com/webcast/btig3/ocx/1596378.

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| 3 |

| --- |